Moderna CEO Stéphane Bancel eyes December for emergency approval of its COVID-19 vaccine

If Moderna moves to file for an emergency use authorisation shortly after the first interim results, the Food and Drug Administration (FDA) may take a few weeks to assess the application before making a decision on it in December

Pfizer, BioNTech start combined trials of COVID-19 vaccine candidate in Japan

The study will recruit 160 people aged from 20 to 85, the firms said in a statement. Earlier, they had agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021.

Pfizer eyes emergency use approval for vaccine in November

The US Food and Drug Administration has said it wants at least two months of safety data before authorizing emergency use of any experimental coronavirus vaccine.

Pfizer urged to wait till November to seek COVID-19 vaccine authorisation

A letter which was obtained by Bloomberg Law and verified by six signatories, was sent on September 25 following the reports that Pfizer’s COVID-19 vaccine clinical trial will yield conclusive results in October which puts the company ahead of Moderna and AstraZeneca in the race of the vaccine.

Pfizer vaccine trial bets on early win against coronavirus

In recent weeks, Pfizer has said it should know by the end of October whether the vaccine, developed together with Germany's BioNTech SE, is safe and effective. If the vaccine is shown to work by then, Pfizer has said it would quickly seek regulatory approval. It has not said what data it would use.

Rich countries have cornered 51% of future COVID-19 vaccine supply: Oxfam

Supply deals have already been agreed for 5.303 billion doses, of which 2.728 billion (51 percent) have been bought by developed countries including the UK, US, Australia, Hong Kong & Macau, Japan, Switzerland and Israel, as well as the European Union

Pfizer’s COVID-19 vaccine update | Candidate’s trial report finds no major safety issues

Pfizer expects “conclusive data” by October-end and promised to make public all its safety and efficacy data in case of emergency authorisation for vaccine

Coronavirus vaccine in US by year-end if regulators approve candidate, says Pfizer CEO

According to Pfizer CEO Albert Bourla, the company’s study will show if there is a “good chance if the product works” by October-end, distribution would depend on license issuances from regulators such as the FDA

Pfizer, BioNTech propose expanding COVID-19 vaccine trial to 44,000 volunteers

The initial target figure for the trial was up to 30,000 participants, which the companies said they expect to reach by next week.

COVID-19 vaccine developers prepare joint safety pledge

The companies would pledge to adhere to high scientific and ethical standards in the conduct of clinical studies and in their manufacturing processes, the Journal report said, citing the draft of a joint statement that is still being finalized.

Selling expected on any rise in market; these 3 stocks could fetch 10-15% return

Though the negative bias is expected in the short term but stock-specific opportunities are likely to keep the traders in high spirits.

Pfizer signs deal to manufacture and supply Gilead's remdesivir for COVID-19 treatment

The US drugmaker would provide contract manufacturing services at its facility in Kansas to produce the drug.

Pfizer, BioNTech to supply 120 million doses of coronavirus vaccine to Japan

The companies said, assuming success of the vaccine in clinical studies, they are on track to seek regulatory review for the vaccine as early as October.

Pfizer Standalone June 2020 Net Sales at Rs 514.89 crore, down 5.42% Y-o-Y

Pfizer Q1 net profit up 10% at Rs 124.45 crore

The company had posted a net profit of Rs 112.81 crore for the corresponding period of the previous fiscal, Pfizer Ltd said in a BSE filing.

Coronavirus vaccine | Pfizer’s US deal sets price cap for other manufacturers: Report

The Pfizer deal at roughly $2 billion deal translates into per dose price of $20. Competitors will, therefore, be forced to offer their coronavirus vaccine in a similar price range

US signs contract with Pfizer for COVID-19 vaccine doses

The agreement is part of President Donald Trump's Operation Warp Speed vaccine program, under which multiple COVID-19 vaccines are being developed simultaneously.

Pfizer-BioNTech potential COVID-19 vaccine shows promise in additional data

The companies said the data also demonstrated an induction of high level of T-cell responses against the novel coronavirus.

Buy Pfizer; target of Rs 4740: ICICI Direct

ICICI Direct is bullish on Pfizer recommended buy rating on the stock with a target price of Rs 4740 in its research report dated July 07, 2020.

Britain signs deals with Pfizer, BioNTech, Valneva for COVID-19 vaccines

Britain had secured 30 million doses of the experimental BioNTech/Pfizer vaccine, and a deal in principle for 60 million doses of the Valneva vaccine, with an option of 40 million more doses if it was proven to be safe, effective and suitable, the ministry said.

Pfizer, BioNTech's coronavirus vaccines get FDA's 'fast track' status

The candidates, BNT162b1 and BNT162b2, are the most advanced of at least four vaccines being assessed by the companies in ongoing trials in the United States and Germany.

BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial

The drug is one of 17 being tested on humans in a frantic global race to find a vaccine the world is counting on to end a pandemic that has infected 10.5 million people and killed more than half a million so far.

Buy Pfizer; target of Rs 4705: ICICI Securities

ICICI Securities is bullish on Pfizer recommended buy rating on the stock with a target price of Rs 4705 in its research report dated June 15, 2020.

Pfizer Standalone March 2020 Net Sales at Rs 502.01 crore, down 6.28% Y-o-Y

Pfizer Q4 profit dips 6% to Rs 103 crore, operating margin contracts

The company said the board has recommended a final dividend of Rs 10 per share for the financial year ended March 31, 2020.